Improved Long-Term Outcome With Chemoradiotherapy Strategies in Esophageal Cancer

被引:63
作者
Swisher, Stephen G. [1 ]
Hofstetter, Wayne
Komaki, Ritsuko
Correa, Arlene M.
Erasmus, Jeremy
Lee, Jeffrey H.
Liao, Zhongxing
Maru, Dipen
Mehran, Reza
Patel, Shital
Rice, David C.
Roth, Jack A.
Vaporciyan, Ara A.
Walsh, Garrett L.
Ajani, Jaffer A.
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA
关键词
PREOPERATIVE CHEMORADIATION; GASTROESOPHAGEAL JUNCTION; CHEMOTHERAPY; CARCINOMA; SURGERY; TRIAL; ADENOCARCINOMA; RESECTION; SURVIVAL;
D O I
10.1016/j.athoracsur.2010.04.061
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Controversy currently exists about the optimum preoperative treatment platform for locoregionally advanced esophageal cancer, namely, preoperative chemoradiotherapy (preoperative C/RT) or preoperative chemotherapy alone. We therefore reviewed sequential phase II/III trials performed at a single institution to assess the impact of preoperative chemotherapy versus preoperative C/RT strategies. Methods. In all, 157 esophageal cancer patients were sequentially enrolled in phase II/III trials at the University of Texas M. D. Anderson Cancer Center from March 27, 1990, to March 8, 2005. The treatment approaches included preoperative chemotherapy, n = 76 (INT 113 and ID90-01); preoperative C/RT, n = 81 (ID96-189 and DM98-349). Analysis was by intention to treat. Factors evaluated included demographics, preoperative staging, type of surgery, pathology, adjuvant therapies, and long-term outcome. Results. Adenocarcinoma predominated (85%), with cT3 (73%) and cN1 (43%). No significant difference was noted between groups in demographics or perioperative mortality. More patients with preoperative C/RT were staged with endoscopic ultrasound (52% versus 9%, p < 0.001). Preoperative C/RT demonstrated increased pathologic complete response (28% versus 4%, p < 0.001) and overall survival (3 years, 48% versus 29%, p = 0.04). Preoperative C/RT was a significant independent predictor of improved overall survival (hazard ratio 0.58, 95% confidence interval: 0.37 to 0.90, p = 0.015) and disease-free survival (hazard ratio 0.55, 95% confidence interval: 0.35 to 0.85, p = 0.007) in multivariable regression. Conclusions. In sequential phase II/III trials involving locoregionally advanced esophageal cancer patients, preoperative C/RT was associated with improved overall and disease-free survival rates (p = 0.046 and p = 0.015, respectively) and increased pathologic complete response (p < 0.001) compared with preoperative chemotherapy. (Ann Thorac Surg 2010;90:892-9) (C) 2010 by The Society of Thoracic Surgeons
引用
收藏
页码:892 / 898
页数:7
相关论文
共 16 条
[1]   FEASIBILITY OF 5 COURSES OF PREOPERATIVE CHEMOTHERAPY IN PATIENTS WITH RESECTABLE ADENOCARCINOMA OF THE ESOPHAGUS OR GASTROESOPHAGEAL JUNCTION [J].
AJANI, JA ;
ROTH, JA ;
PUTNAM, JB ;
WALSH, G ;
LYNCH, PM ;
ROUBEIN, LD ;
RYAN, MB ;
NATRAJAN, G ;
GOULD, P .
EUROPEAN JOURNAL OF CANCER, 1995, 31A (05) :665-670
[2]   Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction [J].
Ajani, JA ;
Walsh, G ;
Komaki, R ;
Morris, J ;
Swisher, SG ;
Putnam, JB ;
Lynch, PM ;
Wu, TT ;
Smythe, R ;
Vaporciyan, A ;
Faust, J ;
Cohen, DS ;
Nivers, R ;
Roth, JA .
CANCER, 2004, 100 (11) :2347-2354
[3]   Long-Term Results of a Randomized Trial of Surgery With or Without Preoperative Chemotherapy in Esophageal Cancer [J].
Allum, William H. ;
Stenning, Sally P. ;
Bancewicz, John ;
Clark, Peter I. ;
Langley, Ruth E. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (30) :5062-5067
[4]  
Bancewicz J, 2002, LANCET, V359, P1727
[5]   Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation [J].
Chirieac, LR ;
Swisher, SG ;
Ajani, JA ;
Komaki, RR ;
Correa, AM ;
Morris, JS ;
Roth, JA ;
Rashid, A ;
Hamilton, SR ;
Wu, TT .
CANCER, 2005, 103 (07) :1347-1355
[6]   PREOPERATIVE CHEMORADIATION FOLLOWED BY TRANSHIATAL ESOPHAGECTOMY FOR CARCINOMA OF THE ESOPHAGUS - FINAL REPORT [J].
FORASTIERE, AA ;
ORRINGER, MB ;
PEREZTAMAYO, C ;
URBA, SG ;
ZAHURAK, M .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (06) :1118-1123
[7]   Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis [J].
Gebski, Val ;
Burmeister, Bryan ;
Smithers, B. Mark ;
Foo, Kerwyn ;
Zalcberg, John ;
Simes, John .
LANCET ONCOLOGY, 2007, 8 (03) :226-234
[8]   Treatment outcomes of resected esophageal cancer [J].
Hofstetter, W ;
Swisher, SG ;
Correa, AM ;
Hess, K ;
Putnam, JB ;
Ajani, JA ;
Dolormente, M ;
Francisco, R ;
Komaki, RR ;
Lara, A ;
Martin, F ;
Rice, DC ;
Sarabia, AJ ;
Smythe, WR ;
Vaporciyan, AA ;
Walsh, GL ;
Roth, JA .
ANNALS OF SURGERY, 2002, 236 (03) :376-385
[9]   Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus [J].
Hulscher, JBF ;
van Sandick, JW ;
de Boer, AGEM ;
Wijnhoven, BPL ;
Tijssen, JGP ;
Fockens, P ;
Stalmeier, PFM ;
ten Kate, FJW ;
van Dekken, H ;
Obertop, H ;
Tilanus, HW ;
van Lanschot, JJB .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (21) :1662-1669
[10]   Long-term results of RTOG trial 8911 (USA intergroup 113): A random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer [J].
Kelsen, David P. ;
Winter, Katryn A. ;
Gunderson, Leonard L. ;
Mortimer, Joanne ;
Estes, Norman C. ;
Haller, Daniel G. ;
Ajani, Jaffer A. ;
Kocha, Walter ;
Minsky, Bruce D. ;
Roth, Jack A. ;
Willett, Christopher G. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (24) :3719-3725